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ABSTRACT 
 
BACKGROUND:  Chronic inflammation and oxidative stress are thought to be involved in colorectal 
cancer (CRC) development. These processes may be contributed to by leakage of bacterial products, 
such as lipopolysaccharide (LPS) and flagellin, across the gut barrier. The objective of this study, 
nested within a prospective cohort, was to examine associations between circulating LPS and flagellin 
serum antibody levels and CRC risk.  
METHODS:  1,065 incident CRC cases (colon n=667; rectal n=398) were matched (1:1) to control 
subjects. Serum flagellin- and LPS-specific IgA and IgG levels were quantitated by ELISA. Multivariable 
conditional logistic regression models were used to calculate odds ratios (OR) and 95% confidence 
intervals (CI), adjusting for multiple relevant confouding factors.  
RESULTS:  Overall, elevated anti-LPS and anti-flagellin biomarker levels were not associated with CRC 
risk. After testing potential interactions by various factors relevant for CRC risk and anti-LPS and anti-
flagellin, sex was identified as a statistically significant interaction factor (pinteraction < 0.05 for all the 
biomarkers). Analyses stratified by sex showed a statistically significant positive CRC risk association 
for men (fully-adjusted OR for highest vs. lowest quartile for total anti-LPS+flagellin =  1.66; 95% CI, 
1.10-2.51; ptrend = 0.049) while a borderline statistically significant inverse association was observed 
for women (fully-adjusted OR= 0.70; 95%CI, 0.47-1.02; ptrend = 0.18).  
CONCLUSION:  In this prospective study on European populations, we found bacterial exposure levels 
to be positively associated to CRC risk among men while in women, a possible inverse association 
may exist.  
IMPACT:  Further studies are warranted to better clarify these preliminary observations.  
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INTRODUCTION 
  
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and a leading cause 
of death worldwide (1). It has been postulated that dietary and metabolic factors, such as energy 
excess and obesity, can cause breakdown of the colonic epithelial barrier function, allowing the 
interaction of innate immune system with bacterial products such as lipopolysaccharide (LPS), also 
known as endotoxin (2). The human gastrointestinal (GI) tract is colonized by a complex community 
of approximately 1014 commensal bacteria, representing approximately 1,000 species (3). Colonic 
microbiota are being increasingly recognized as important contributors to GI health and likely also to 
CRC development (4).  
LPS is an integral part of the outer membrane of Gram-negative bacterial cell wall and also 
has a major role in both acute and chronic inflammation (5). A related bacterial product is flagellin, 
the primary structural component of flagella and a dominant target of humoral immunity in response 
to infection (6). Emerging evidence suggests that an overabundance of bacterial LPS from the gut 
microbiota may trigger chronic inflammation and increased production of pro-inflammatory 
cytokines and increased reactive oxygen species (2, 7). These pro-inflammatory cytokines can 
activate the nuclear factor κβ (NF-κβ) pathway, which has been implicated in cell proliferation and 
DNA damage leading to carcinogenesis (8). Chronic inflammation has been associated with increased 
risk of CRC by several studies (9). Thus, hypothetically, long term exposure to the localized 
inflammatory responses resulting from LPS exposure may promote CRC development.  
Direct in vivo measurement of LPS and flagellin levels is challenging, in part because their 
appearance in blood and organs is sporadic and partly because their presence is quite transient. 
Hence, a few recent studies have measured levels of immunoglobulins against LPS and flagellin, 
whose levels can persist for months following exposure to these products, in an attempt to broadly 
assess  systemic exposure to these gut microbial products and probe their potential associations with 
various disease states (10, 11). In a recent study by Ziegler et al. (10), flagellin- and LPS-specific serum 
immunoglobulin levels (IgM, IgA, and IgG) were markedly increased in patients with short bowel 
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syndrome (SBS) compared with healthy controls. In another study, IgA and IgG antibodies specific for 
flagellin monomers were shown to be a target of the elevated adaptive immune response associated 
with Crohn’s disease, a chronic inflammatory disease of the GI tract (12). Another line of evidence 
has emerged from a recent animal study which explored the intricate relationship between intestinal 
barrier function, microbial environment and inflammation in CRC by demonstrating that an 
inflammatory microenvironment promotes CRC progression in mice (13). The study highlighted that 
defective intestinal barrier function at tumour sites facilitates invasion of microbial products 
triggering inflammation and subsequent tumour growth.   
While the role of microbiota in development of colorectal carcinogenesis has been explored 
in basic science and animal studies (13, 14), there is currently no direct epidemiologic evidence for 
the role of endotoxemia and gut barrier dysfunction in CRC aetiology. In the present study, we aimed 
to examine the association between serum LPS- and flagellin-specific immunoglobulin levels (IgA, and 
IgG) and risk of CRC development within a nested case-control study in the European Prospective 
Investigation into Cancer and Nutrition (EPIC) cohort.       
 
MATERIALS AND METHODS 
  
Study population and data collection 
 
We used a case-control design nested within the EPIC cohort, a large prospective cohort 
study with over 520,000 subjects enrolled from 23 centres in 10 Western European countries 
(Denmark, France, Greece, Germany, Italy, Netherlands, Norway, Spain, Sweden, and United 
Kingdom). Details of the design and methods of the EPIC study, including information on dietary 
assessment methods, blood collection protocols, and follow-up procedures, have been previously 
described (15). Briefly, individuals who were eligible for the study were selected from the general 
population of a specific geographical area, town, or province. Exceptions included the French sub-
cohort, which is based on members of the health insurance system or state-school employees, and 
the Utrecht (Netherlands) sub-cohort, which is based on women who underwent screening for breast 
cancer. Between 1992 and 1998, standardized lifestyle and personal history questionnaires, 
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anthropometric data and blood samples were collected from most participants at recruitment. Diet 
over the previous 12 months was assessed at recruitment by validated country-specific 
questionnaires designed to ensure high compliance and improved measures of local dietary habits 
(16).  
In each of the study centres, fasting or non-fasting blood samples were drawn from 
participants who provided a blood sample and stored at 5°C  to 10°C, protected from light, and 
transported to local laboratories for processing and aliquoting as previously described (15, 16). In all 
countries, except Denmark and Sweden, blood was separated in the local EPIC centres and stored at 
the International Agency for Research on Cancer (Lyon, France; -196°C, nitrogen vapour).  In 
Denmark, blood samples were stored locally at -150°C under nitrogen vapour.  In Sweden, samples 
were stored in -80°C freezers.   
Follow-up for cancer incidence and vital status  
 
Vital status follow-up (98.4% complete) is collected by record linkage with regional and/or 
national mortality registries in all countries except Germany and Greece, and the Italian centre of 
Naples, where data are collected actively. Incident cancer cases were determined through record 
linkage with regional cancer registries (Denmark, other Italian centres, the Netherlands, Norway, 
Spain, Sweden, and United Kingdom; completed up to June 2003) or via a combination of methods, 
including linkage with health insurance records, contacts with cancer and pathology registries, and 
active follow-up through study subjects or their next-of-kin (France, Germany, and Greece; 
completed up to June 2002).  Follow-up began at the date of enrolment and ended at the date of 
CRC diagnosis.     
Nested case-control study design and selection of study subjects 
 
Case ascertainment and selection 
Eligible CRC cases were first incident, histologically-confirmed cases diagnosed within the 
EPIC study population. Colon cancers were defined as tumours in the cecum, appendix, ascending 
colon, hepatic flexure, transverse colon, splenic flexure, and descending and sigmoid (C18.0 – C18.7, 
on November 2, 2016. © 2016 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on January 11, 2016; DOI: 10.1158/1055-9965.EPI-15-0798 
8 
  
according to the 10th Revision of the International Statistical Classification of Diseases, Injury, and 
Cause of Death), as well as tumours that were overlapping or unspecified (C18.8 and C18.9). Rectal 
cancers were defined as tumours occurring at the recto-sigmoid junction (C19) or rectum (C20). 
Subjects with anal canal tumours were excluded from the study. CRC is defined as a combination of 
the colon and rectal cancer cases. After exclusions of 23 subjects with missing laboratory 
measurements of LPS or flagellin and 49 subjects with incomplete matching, a total of 1,065 incident 
CRC cases (colon n = 667; rectal n = 398) with available biomarker measurements were included in 
the study.   
Control selection 
For each identified cancer case, one control was matched by incidence density sampling by 
age (within 2.5 years), gender, administrative centre, time of the day at blood collection, and fasting 
status at the time of blood collection (less than 3 hours, 3-6 hours, and more than 6 hours). Women 
were additionally matched on menopausal status (premenopausal, peri-menopausal, 
postmenopausal, or surgically menopausal). Premenopausal women were further matched on phase 
of the menstrual cycle at blood collection and postmenopausal women were matched on current use 
of hormone replacement therapy. Controls were defined as free of cancer, except non-melanoma 
skin cancer, at the time of diagnosis of the case.   
Laboratory biomarker measures for serum anti-flagellin- and anti-LPS-specific immunoglobulins 
 
Serum anti-LPS- and anti-flagellin-specific IgA and IgG levels were quantitated by enzyme-
linked immunosorbent assay (ELISA) at Georgia State University (Atlanta, GA, USA), as previously 
described (10, 11). Briefly, microtiter plates (DYNEX) were coated overnight with purified laboratory 
made flagellin (100 ng/well) or purified E.coli LPS (2 μg/well; from E.coli 0128: B12, Sigma, Catolog No. 
2887) in 9.6 pH bicarbonate buffer. Serum samples from cases and controls diluted 1:200 were 
applied to wells coated with flagellin or LPS. After incubation and washing, the wells were incubated 
either with IgG coupled to horseradish peroxidase (GE, Catalog No. 375112) or, in the case of Ig-A-
specific antibodies, with peroxidase-labeled IgA (KPL, Catolog No. 14-10-01). Quantitation of total 
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immunoglobulins was performed using the colorimetric peroxidase substrate tetramethylbenzidine 
(TMZ), and optical density (OD) was read at 450 nm and 540 nm (the difference was taken to 
compensate for optical interference from the plate), with an ELISA plate reader. Data are reported as 
OD corrected by subtracting background (determined by readings in blank samples) and are 
normalized to each plate’s control sample, which was prepared in bulk, aliquoted, frozen, and 
thawed daily as used. Only adjusted OD were used in the analysis. Standardization was performed 
using preparations of known concentrations of IgA and IgG. Because previously performed assays for 
these biomarkers in replicates had a very low intra-assay coefficient of variation (<5%) (17), our 
samples were analysed in singleton to minimize bio-sample volume requirement, cost and time. 
Inter-assay coefficients of variation were between 3.8% and 6.8%. For all analyses, cases and 
matched controls were run in the same batch, and the case-control status of the samples was 
blinded to laboratory technicians.         
In the present study, secondary use was made of relevant biomarker measures that had 
been conducted previously on the same series of subjects (18-20). Briefly, measurements of glycated 
haemoglobin (HbA1c) were done on erythrocyte hemolysate using high performance liquid 
chromatography method (Bio-Rad Variant II instrument, Bio Lad Laboratories, Hercules, California) 
with intra-batch coefficient of variations of 2.5% (18). High-sensitivity C-reactive protein (hs-CRP) 
concentrations were measured using a high-sensitivity assay (Beckman-Coulter, Woerden, the 
Netherlands) on a Synchron LX-20 Pro autoanalayzer (Beckman-Coulter). The inter-assay coefficients 
of variation were 6.0% - 6.5% at various concentrations of hs-CRP (19).    
Statistical analysis 
 
The distributions of selected characteristics between colon and rectal cases and the matched 
controls were compared. Normality of each biomarker was checked by visual inspection, and all were 
deemed to be approximately normal. Each individual biomarker, as well as, anti-flagellin (flagellin 
IgA)+flagellin IgG), anti-LPS (LPS IgA+LPS IgG), and anti-flagellin+LPS exposure (flagellin IgA + flagellin 
on November 2, 2016. © 2016 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on January 11, 2016; DOI: 10.1158/1055-9965.EPI-15-0798 
10 
  
IgG + LPS IgA + LPS IgG) levels were categorized into quartiles based on the distribution among the 
controls with the lowest quartile as the reference category.  
Conditional logistic regression was used to estimate the odds ratios (OR) and 95% confidence 
intervals (CI) of CRC, and by anatomical sub-site of cancers of colon and rectum in relation to levels of 
each circulating biomarkers. Risk estimates were computed from both univariate analyses adjusted 
for the matching factors (matching-adjusted), and multivariable analyses, with additional 
adjustments for established confounding variables (fully-adjusted), including smoking status 
(status/duration/intensity of smoking), body mass index (BMI, kg/m2), waist circumference (cm), 
education level, total alcohol consumption (g/d), physical activity (sex-specific combined total 
physical activity index), total energy intake (kcal/day), and total daily intakes of fibre (g/day), fruits 
and vegetables (g/day), and red/processed meats (g/day) (21-26). For all models, collinearity was 
assessed and tests for linear trend were performed using a score variable with values from 1 to 4 
included in the model, consistent with the quartile grouping. 
We evaluated interactions by several factors relevant for CRC risk that may be also related to 
anti-LPS- and anti-flagellin-IgA and -IgG concentrations, total bacterial load and/or to colonic barrier 
function (27). Sex and tumour location (colon, rectum) were proposed a priori as potential 
interactions so results are presented stratified by these factors, as well as combined. Other variables 
(i.e. hs-CRP, waist circumference, BMI, dietary fat, and alcohol intake) were studied for hypothesis 
generation analyses. Continuous analyses were conducted using a cross-product term of each 
biomarker and potential interaction term in the model, followed by a likelihood ratio test. Discrete 
analyses were also undertaken for hs-CRP, waist circumference, BMI, dietary fat, and alcohol intake 
by including an interaction term formed by the product of the total-anti-flagellin+LPS tertile (cut-
points: <5.58, 5.58 to < 7.19, > 7.19) and the sex-specific dichotomized high and low categories of the 
potential interaction. As with continuous analysis, a likelihood ratio test was used to assess statistical 
significance.   
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As a sensitivity analysis, we repeated the main multivariable-adjusted models after excluding 
cases that occurred in the first 2 years of follow-up and their matched controls to avoid possible 
reverse causality, as well as after exclusion of countries with lowest (Denmark) and highest (Greece) 
anti-LPS- and anti-flagellin exposure levels.  
Conditional logistic restricted cubic spline models were used to explore possible deviation 
from linear relationships between each biomarker and CRC, with 4 knots specific at the median of 
each quartile of biomarker levels (28).   
A two-tailed p-value < 0.05 was considered to be statistically significant. All statistical 
analyses were performed with SAS version 9.3 (SAS Institute, Cary, NC) statistical software package. 
 
RESULTS 
 
Baseline characteristics of cases and controls 
Selected baseline characteristics of the colon and rectal cases and their matched controls are 
compared in Table 1. Colon and rectal cancer cases were on average 58.8 years and 58.1 years old, 
respectively. Both colon and rectal cancer cases were more likely to be current smokers, inactive, 
had higher education, higher total daily energy, and consume less fruit and vegetable than their 
matched controls. For colon cancer, female cases had lower median concentrations of anti-flagellin-
IgA (1.05 vs. 1.17), anti-LPS-IgA (1.56 vs. 1.71), and anti-LPS-IgG (1.36 vs. 1.44), than their matched 
controls, while the concentrations of each of these serological biomarkers were higher in cases than 
controls in men (anti-flagellin-IgA: 1.33 vs. 1.30; anti-LPS-IgA: 1.83 vs. 1.68; anti-LPS-IgG: 1.45 vs. 
1.37). For rectal cancer, concentrations of each of the serological biomarkers were higher in cases 
than controls in women, except anti-LPS-IgA, where cases had lower concentrations than controls 
(1.38 vs. 1.48). On the other hand, concentrations of all the serological biomarkers were slightly 
lower in male rectal cancer cases than controls, except anti-flagellin-IgA, where cases had higher 
concentrations than controls (1.29 vs. 1.17).  
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Associations of anti-flagellin- and anti-LPS- IgA and IgG with CRC  
All models found no association between CRC and biomarkers of either anti-LPS or anti-
flagellin (Supplemental Table S1). However, when analyses were stratified by sex, a significant 
interaction of the CRC-LPS/flagellin risk association (total-anti-flagellin+LPS, pinteraction < 0.05) was 
observed.  Among men, there was a significant, positive association between CRC risk and levels of 
total-anti-flagellin+LPS exposure (Table 2) with a fully-adjusted OR of 1.66 (95% CI, 1.10-2.51) 
comparing the higest vs. lowest quartiles, and a significant test for trend (ptrend 0.049).  In contrast, 
among women, there were inverse associations with CRC risk. Anti-flagellin-IgA was negatively 
associated with risk of CRC (fully-adjusted OR = 0.65 comparing highest vs. lowest quartiles; 95% CI, 
0.44-0.96; ptrend = 0.02). In addition, there was a trend of significant inverse association between anti-
LPS-IgA and risk of CRC with ptrend of 0.02. Unlike among men, the levels of total-anti-flagellin+LPS 
exposure were also negatively related to CRC risk, though the association did not reach significance 
(fully-adjusted OR = 0.70 comparing highest vs. lowest quartiles; 95% CI, 0.47-1.02; ptrend = 0.18). 
Associations of anti-LPS and anti-flagellin concentrations with colon and rectal cancer stratified by 
sex  
In stratified-analyses by anatomical sub-sites (pheterogenity = 0.64), colon cancer risk in men 
continued to be significantly positively associated with total-anti-flagellin+LPS concentrations (fully-
adjusted OR = 1.80 comparing highest vs. lowest quartiles; 95% CI, 1.04-3.10; ptrend < 0.049) (Table 3), 
as well as with total-anti-LPS (fully-adjusted OR = 1.97; 95% CI, 1.15-3.39; ptrend = 0.01). However, 
among women, higher concentrations of several biomarkers remained associated with reduced risk 
of colon cancer with fully-adjusted ORs of 0.59 (95% CI, 0.37-0.93), 0.57 (95% CI, 0.35-0.91), and 0.62 
(95% CI, 0.39-0.98), comparing those with highest quartiles of anti-flagellin-IgA, anti-LPS-IgG, and 
total-anti-LPS to reference, respectively (Table 3).  
No significant association was observed between risk of rectal cancer and any of the 
measures for either men or women (Table 4).  
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Interactions with inflammation, body size, and dietary fat 
The analysis of the interaction between total-anti-LPS+flagellin level and inflammation (hs-
CRP), body size (waist circumference and BMI), dietary fat intake, and alcohol consumption showed 
that, among men, the positive association between CRC risk and total-anti-LPS+flagellin level was 
stronger at higher levels of hs-CRP (OR = 2.35 comparing highest hs-CRP and highest tertile of total-
anti-LPS+flagellin vs. lowest hs-CRP and lowest tertile of total-anti-LPS+flagellin; 95% CI, 1.45-3.81; 
pinteraction=0.002), waist circumference (OR = 1.97; 95% CI, 1.24-3.13; pinteraction=0.01), BMI (OR = 1.77; 
95% CI, 1.13-2.78; pinteraction=0.03), and alcohol (OR = 1.71 ; 95% CI, 1.09-2.69; pinteraction=0.02). No 
interaction was observed in any of these factors among women (pinteraction>0.05 for all) (Supplemental 
Table S2).  
Sensitivity analysis 
 
  After excluding cases that occurred during the first two years of follow-up and their matched 
controls to avoid possible reverse causality, the findings did not change substantially for any of the 
serologic biomarkers in both colon and rectal cancers for either sex (Supplemental Table S3). Similar 
results were observed after excluding participants in the countries with lowest (Denmark) and 
highest (Greece) anti-LPS- and anti-flagellin biomarker exposure levels (data not shown). Spline 
models showed that the associations between anti-flagellin and anti-LPS biomarkers and risk of colon 
or rectal cancers were linear (data not shown). 
 
DISCUSSION 
  
In this nested case-control study, we investigated the associations of serologic bacterial 
markers of anti-LPS- and anti-flagellin-IgA and IgG with CRC risk. No significant associations were 
observed with CRC risk, but sub-group analyses by sex revealed a positive association in men for anti-
LPS and anti-flagellin markers combined, while in women the associations were inverse.  
One key mechanism whereby microbiota may influence CRC development is through 
intestinal barrier dysfunction (29). There is an emerging recognition of the ability of the GI tract to 
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regulate the trafficking of macromolecules between the environment and the host through a barrier 
mechanism (30). A growing body of evidence supports a link between increased intestinal 
permeability and several GI disorders such as IBD (31), which is a known risk factor for CRC. It has 
been suggested that some dietary / lifestyle exposures (e.g. total fat intake, body weight) and 
physiological factors (e.g. inflammation) may exacerbate intestinal permeability leading to increased 
exposure of the colonic epithelium to endotoxins and greater leakage of endotoxins into the systemic 
circulation (32, 33). 
The impact of bacteria on the development of CRC has been mostly studied from the 
perspective of inflammatory responses. It has become clear that the microbiota has a major 
influence on immune responses and chronic inflammation is a well-established risk factor for CRC 
(34). LPS have been suggested to be involved in CRC development through their roles in stimulating 
the immune system by binding cell-surface Toll-like receptor (TLR)-4, the predominant receptor for 
LPS, and activating transcription factors, such as NF-κB, resulting in an increased production of pro-
inflammatory cytokines, such as TNF-α, interleukin (IL)-1, and IL-6 (35). Flagellin is recognized by both 
TLR-5 and the NLRC4 inflammasome, which elicits immune signals by activation of NF-κB and 
caspase-1 respectively, and hence promotes systemic inflammation by production of multiple 
inflammatory cytokines (36, 37).  
Despite a growing body of evidence from in vitro and in vivo studies on the role of the 
microbiome in the development of CRC, limited epidemiological studies have thus far been available 
to show associations between bacterial endotoxin exposure and colorectal adenomas or CRC. Two 
recent studies have observed a positive relationship between endotoxin and colorectal adenomas 
(38, 39) with the strongest associations observed for dysplastic lesions (39). Our results showing a 
positive association of serum LPS and flagellin biomarkers and CRC in men are in line with the results 
of these studies on the role of bacteria exposure in CRC carcinogenesis. However, these studies did 
not report sex stratified findings so do not permit compassion with our findings in women.  
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We observed in hypothesis generating analyses that the positive associations between anti-
LPS and anti-flagellin levels and risk of CRC in men were stronger in higher levels of hs-CRP, waist 
circumference, BMI, and alcohol intake, results which, if replicated, suggest that these factors may 
play a role in exacerbating the CRC promotive effects of LPS and flagellin. Also worthy of examination 
is the possibility that body size, inflammation, and alcohol intake may influence intestinal 
permeability and so lead to increased exposure to bacterial products.   
Based on the observations from the above mentioned studies, an inverse association 
between anti-LPS and anti-flagellin levels and CRC risk that we observed among women was 
unexpected. However, other studies have previously demonstrated inverse associations between 
environmental endotoxin exposures and the risk of lung and other cancers in occupational settings. 
Protective effects of environmental/occupational endotoxin exposure on lung cancer have been 
consistently demonstrated in studies of cotton textile due to raw cotton fibre or dust being 
contaminated with bacterial endotoxin (40-42) and farming industries (43), protection hypothesized 
to result from potential anti-carcinogenic effects of endotoxin mediated by the innate and acquired 
immune systems (42). Differences between men and women have also been observed among cotton 
plant workers where there was an increased risk of colon and liver cancers in men while women had 
lower risk of rectal/anal and liver cancers (44). However, these previous studies were based on 
occupational cohorts with high endotoxin exposures while the endotoxin measures of our study 
subjects are likely to be derived largely from the colonic bacteria rather than the environment. 
Therefore, careful interpretation is required when comparing our findings to those of previous 
studies looking at specific subject groups. 
Two mechanisms may be involved in the differences between men and women which we 
observed in the associations between endotoxin and risk of CRC. First, complex interaction between 
the innate and adaptive immune systems are important underlying mechanisms of associations 
between endotoxin and carcinogenesis (45). The differences between men and women are observed 
could therefore result from well-established sex-based differences in the immune systems that result 
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in women having a more vigorous immune response, both cellular and humoral, than men (46-48). 
Second, it is possible that the composition of microbiota could differ in men and women as sex 
differences have been observed in the composition of skin microbiota (49). It is therefore possible 
that different organisms might have different associations with colon carcinogenesis and so account 
for the differences between men and women we observed. Such possibilities have yet to be studied 
in detail.  
Lastly, it is possible that our gender-specific observations are due to chance, despite the 
relatively large size of the present study. Therefore, replication of these findings and deeper 
exploration of the sex-specific bacterial exposure and CRC hypothesis is required.   
The present study has several strengths. Our study is the largest prospective cohort so far to 
investigate bacterial exposures and CRC risk. Therefore, we had a large enough sample size to be able 
to stratify by anatomical sub-sites of CRC and by gender. To our knowledge, no previous studies on 
bacterial exposure and CRC risk have had a sufficiently large enough sample size to conduct stratified 
analyses.  
We also have several limitations in the study. First, since the gut is colonized by complex 
bacterial communities, elevated anti-LPS or anti-flagellin levels alone may not be sufficient to 
promote inflammation and tumour progression (38). Another limitation is that we measured the 
anti-LPS and anti-flagellin concentrations in serum, not in the colonic mucosa, which could be more 
relevant for colorectal carcinoma formation. Indeed, the assay we applied measures serum 
immunoreactivity to common bacterial flagellin monomers, which have highly conserved regions 
common to many flagellins in the microbiota. Although differences in such flagellin immunoreactivity 
have been thought to reflect differences in gut permeability, they may also arise from differences in 
microbiota composition and/or gene expression. Thus, better clarification of the source and 
biological properties of these compounds is a task for future research. Moreover, bio-samples were 
available from only from the time of recruitment into the cohort and thus we only had a single blood 
measure taken at one point in time.  
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 In summary, we found no overall association between bacterial exposure levels, measured 
by anti-LPS- and anti-flagellin-IgA and IgG, and risk of CRC. However, in sub-group analysis by sex, we 
found some biomarker levels to be positively associated with CRC risk among men while they were 
inversely associated with CRC risk among women. Further studies are warranted to elucidate the 
underlying mechanisms of bacterial exposure and CRC by sex as well as the sex-specific role of 
inflammation and immune response on CRC risk. 
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Table 1:  Baseline characteristics of incident colon and rectal cancer cases and matched controls in the EPIC Cohort 
Characteristics 
 
Colon Cancer Rectal Cancer
Cases Controls Cases Controls 
Number 667 667 398 398 
Age, years, mean (SD) 
     At recruitment 
     At blood collection 
 
58.8 (7.2) 
59.0 (7.3) 
 
58.8 (7.3) 
59.0 (7.3) 
 
58.1 (6.9) 
58.1 (6.8) 
 
58.0 (6.9) 
58.1 (6.8) 
Women, n (%) 369 (55.3) 369 (55.3) 187 (47.0) 187 (47.0)
Body mass index, kg/m2, mean (SD) 26.8 (4.5) 26.3 (3.9) 26.6 (4.1) 26.4 (3.9)
Waist circumference, cm, mean (SD) 90.4 (13.2) 88.0 (12.2) 90.3 (13.1) 89.5 (13.1) 
Waist/hip ratio, mean (SD) 0.9 (0.1) 0.9 (0.1) 0.9 (0.1) 0.9 (0.1) 
Smoking status / duration / intensity, n (%) 
     Never-smoker 
     Ex-smokers, duration of smoking < 10 years 
     Ex-smokers, duration of smoking > 10 years 
     Ex-smokers, missing duration of smoking 
     Smokers, < 15 cigarettes a day 
     Smokers, > 15 to < 25 cigarettes a day 
     Smokers, > 25 cigarettes a day 
     Missing smoking status 
 
277 (41.5) 
40 (6.0) 
165 (24.7) 
16 (2.4) 
109 (16.3) 
43 (6.5) 
9 (1.4) 
8 (1.2) 
 
297 (44.5) 
43 (6.5) 
164 (24.6) 
13 (1.9) 
97 (14.5) 
39 (5.9) 
6 (0.9) 
 8 (1.2)  
 
155 (38.9) 
21 (5.3) 
104 (26.1) 
4 (1.0) 
79 (19.9) 
24 (6.0) 
8 (2.0) 
3 (0.8) 
 
160 (40.2) 
30 (7.5) 
91 (22.9) 
8 (2.0) 
63 (15.8) 
35 (8.8) 
5 (1.3) 
6 (1.5) 
Physical activity, n (%) 
     Inactive 
     Moderately inactive 
     Moderately active 
     Active 
     Missing/unspecified 
107 (16.0) 
202 (30.3) 
292 (43.8) 
62 (9.3) 
4 (0.6) 
78 (11.7) 
210 (31.5) 
296 (44.4) 
77 (11.5) 
  6 (0.9) 
59 (14.8) 
116 (29.2) 
176 (44.2) 
47 (11.8) 
0 
58 (14.6) 
103 (25.9) 
167 (42.0) 
61 (15.3) 
9 (2.2) 
Education, % 
     None/primary school 
     Technical/professional school 
     Secondary school 
     University or higher 
     Missing/unspecified 
259 (39.1) 
158 (23.8) 
111 (16.7) 
117 (17.6) 
18 (2.7) 
292 (44.0) 
161 (24.2) 
87 (13.1) 
109 (16.4) 
15 (2.3) 
150 (38.0) 
106 (26.8) 
54 (13.7) 
76 (19.2) 
9 (2.3) 
163 (41.2) 
109 (27.5) 
43 (10.9) 
76 (19.2) 
5 (1.2) 
Premenopausal women, n (%) 41 (11.1) 42 (11.4) 16 (8.6) 16 (8.6)
Hormone Replacement Therapy use, n (%) 42 (11.5) 40 (10.9) 19 (10.3) 19 (10.3) 
Alcohol consumption, g/d, median (IQR) 8.6 (1.3-22.4) 8.4 (1.5-21.1) 11.6 (2.4-31.5) 10.5 (2.2-25.2) 
Dietary Intakes 
     Total energy, kcal/d, median (IQR) 
 
2066.5 (1693.2-2505.2) 
 
2058.7 (1729.2-2453.1) 
 
2158.6 (1726.7-2568.8) 
 
2093.8 (1721.3-2537.8) 
     Total fats, g/d, median (IQR) 
     Fibre intake, g/d, median (IQR) 
     Fruit and vegetable intake, g/d, median (IQR) 
77.4 (60.4-97.5)
22.2 (17.2-27.3) 
368.9 (244.73-523.9) 
77.1 (61.8-97.0) 
23.0 (18.4-27.4) 
417.0 (267.3-566.0) 
79.2 (60.2-103.4)
22.0 (18.2-27.7) 
361.9 (247.8-503.3) 
79.6 (63.0-100.5)
22.8 (17.8-28.3) 
369.9 (251.7-534.4) 
o
n
 N
ovem
ber 2, 2016. © 2016 Am
erican Association for Cancer Research. 
cebp.aacrjournals.org 
D
ow
nloaded from
 
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author M
anuscript Published O
nlineFirst on January 11, 2016; DO
I: 10.1158/1055-9965.EPI-15-0798 
22 
  
     Fish and shellfish intake, g/d, median (IQR) 
     Red meat intake, g/d, median (IQR) 
     Processed meat intake, g/d, median (IQR) 
Fasting status, % 
     Yes 
     No 
     In between 
27.0 (14.8-46.7) 
48.3 (25.5-77.1) 
25.0 (13.0-40.8) 
 
25.5 
48.9 
25.6 
29.0 (14.5-50.3) 
48.3 (25.8-76.5) 
23.4 (12.5-41.6) 
 
25.5 
48.9 
25.6 
28.0 (16.0-51.3) 
55.2 (33.6-83.1) 
27.3 (13.9-47.5) 
 
18.6 
57.9 
23.4 
30.0 (14.0-51.5) 
54.0 (31.7-81.6) 
26.4 (13.0-46.5) 
 
18.6 
57.9 
23.4 
Blood Biomarkers 
     Hs-CRP, mg/l, median (IQR) 
          Men           
          Women 
 
 
2.81 (1.25-5.15) 
3.36 (1.28-5.88) 
 
 
1.96 (0.89-4.26) 
2.59 (1.25-5.11) 
 
 
2.13 (1.00-4.31) 
2.60 (1.00-4.72) 
 
 
2.16 (0.98-4.21) 
2.56 (1.09-4.20) 
     Cholesterol, mmol/L, median (IQR) 
          Men 
          Women 
     HDL, mmol/L, median (IQR) 
          Men 
          Wome 
     LDL, mmol/L, median (IQR) 
          Men 
          Women 
 
6.07 (5.24-6.86) 
6.43 (5.65-7.30) 
 
1.23 (1.04-1.48) 
1.51 (1.25-1.78) 
 
3.99 (3.42-4.72) 
4.24 (3.56-5.03) 
 
6.21 (5.54-6.90) 
6.61 (5.77-7.42) 
 
1.29 (1.09-1.60) 
1.53 (1.29-1.90) 
 
4.17 (3.57-4.70) 
4.30 (3.55-5.06) 
 
6.27 (5.57-7.05) 
6.55 (5.70-7.30) 
 
1.28 (1.09-1.56) 
1.63 (1.33-1.86) 
 
4.16 (3.55-4.86) 
4.23 (3.43-4.85) 
 
6.22 (5.52-7.00) 
6.80 (6.08-7.67) 
 
1.27 (1.07-1.52) 
1.61 (1.33-1.86) 
 
4.23 (3.41-4.90) 
4.31 (3.70-5.33) 
     Glycated haemoglobin mg/L, median (IQR) 
           Men 
           Women 
     Anti-Flagellin-IgA, OD, median (IQR) 
          Men 
          Women 
     Anti-Flagellin-IgG, OD, median (IQR) 
          Men 
          Women 
     Anti-LPS-IgA, OD, median (IQR) 
          Men 
          Women 
     Anti-LPS-IgG, OD, median (IQR) 
          Men 
          Women 
 
5.7 (5.5-6.1) 
5.8 (5.5-6.1) 
 
1.33 (0.94-1.79) 
1.05 (0.76-1.52) 
 
1.97 (1.42-2.55) 
2.03 (1.50-2.63) 
 
1.83 (1.29-2.41) 
1.56 (1.19-2.16) 
 
1.45 (1.06-1.91) 
1.36 (1.00-1.83) 
 
5.7 (5.5-6.0) 
5.7 (5.5-5.9) 
 
1.30 (0.92-1.78) 
1.17 (0.80-1.67) 
 
1.99 (1.42-2.51) 
2.00 (1.50-2.64) 
 
1.68 (1.28-2.14) 
1.71 (1.22-2.24) 
 
1.37 (1.08-1.83) 
1.44 (1.09-1.93) 
 
5.7 (5.5-6.0) 
5.8 (5.5-6.0) 
 
1.29 (0.85-1.68) 
1.01 (0.68-1.47) 
 
1.88 (1.31-2.53) 
2.10 (1.48-2.61) 
 
1.62 (1.22-2.26) 
1.38 (1.06-1.87) 
 
1.28 (1.01-1.85) 
1.43 (1.08-1.82) 
 
5.8 (5.5-6.1) 
5.6 (5.5-5.9) 
 
1.17 (0.84-1.67) 
0.95 (0.70-1.45) 
 
1.92 (1.43-2.61) 
2.02 (1.46-2.58) 
 
1.66 (1.24-2.03) 
1.48 (1.04-1.94) 
 
1.35 (1.00-1.85) 
1.32 (1.01-1.73) 
NOTE:  Cases and controls were matched on age (within 2.5 years), gender, administrative centre, hormone therapy, fasting status, and date of blood collection (within 45 days). 
Abbreviations:  SD = standard deviation; IQR = inter-quartile range; hs-CRP = high-sensitivity C-reactive protein; HDL = high density lipoprotein; LDL = low density lipoprotein; LPS = 
lipopolysaccharide; OD = optical density; IgA = immunoglobulin A; IgG = immunoglobulin G  
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Table 2:  ORs (95% CI) for risk of CRC by quartile of baseline biomarkers of anti-LPS- and anti-flagellin-IgA and 
IgG: Stratified by sex  
 
Serum Immunoglobulins against 
LPS and Flagellin, OD 
Continuous Quartiles* 
Ptrend (per 1-SD Increase) 
OR(95% CI) 
Q1 
OR 
Q2 
OR (95% CI) 
Q3 
OR (95% CI) 
Q4 
OR (95% CI) 
MEN  
Anti-Flic-IgA, no. Ca/Co 
          SD/Cut-point 
          Matching-adjusted Modelᵃ  
          Fully-adjusted Modelb 
509/509 
0.72 
1.03 (0.91-1.18) 
1.01 (0.88-1.16) 
94/102
< 0.81 
     1.00 
1.00 
120/128
> 0.81 to < 1.18 
1.01 (0.70-1.46) 
1.07 (0.73-1.58) 
147/138 
> 1.18 to < 1.68 
1.17 (0.81-1.70) 
1.26 (0.85-1.85) 
148/141
          > 1.68 
1.16 (0.80-1.68) 
1.16 (0.78-1.71) 
 
0.35 
0.39 
Anti-Flic-IgG, no. Ca/Co 
          SD/Cut-point 
          Matching-adjusted Modelᵃ  
          Fully-adjusted Modelb 
509/509 
0.78 
0.96 (0.84-1.10) 
0.99 (0.85-1.14) 
145/138 
< 1.46 
 1.00 
1.00 
121/125 
>1.46 to < 1.98 
0.92 (0.64-1.30) 
0.96 (0.66-1.38) 
124/124 
> 1.98 to < 2.58 
0.94 (0.65-1.37) 
0.96 (0.65-1.43) 
119/122 
> 2.58 
0.92 (0.63-1.33) 
0.99 (0.66-1.47) 
 
 
0.69 
0.95 
Anti-LPS-IgA, no. Ca/Co 
          SD/Cut-point 
          Matching-adjusted Modelᵃ  
          Fully-adjusted Modelb 
509/509 
0.72 
 1.18 (1.03-1.37) 
 1.17 (1.01-1.36) 
118/115 
< 1.21 
1.00 
1.00 
116/134 
> 1.21 to < 1.66 
  0.84 (0.58-1.23) 
0.82 (0.55-1.21) 
120/138 
> 1.66 to < 2.13 
  0.87 (0.59-1.28) 
0.82 (0.54-1.23) 
155/122 
> 2.13 
1.32 (0.88-1.98) 
1.26 (0.82-1.94) 
 
 
0.14 
0.27 
Anti-LPS-IgG, no. Ca/Co 
          SD/Cut-point 
          Matching-adjusted Modelᵃ  
          Fully-adjusted Modelb 
Total-Anti-Flic, no. Ca/Co 
          SD/Cut-point 
          Matching-adjusted Modelᵃ  
          Fully-adjusted Modelb 
Total-Anti-LPS, no. Ca/Co 
          SD/Cut-point 
          Matching-adjusted Modelᵃ  
          Fully-adjusted Modelb 
Total-Anti-Flic & LPS, no. Ca/Co 
          SD/Cut-point 
          Matching-adjusted Modelᵃ  
          Fully-adjusted Modelb 
509/509 
0.61 
 1.08 (0.96-1.23) 
1.12 (0.98-1.28) 
509/509 
1.23 
 0.99 (0.87-1.13) 
1.00 (0.87-1.15) 
509/509 
 1.11 
    1.17 (1.02-1.34) 
1.18 (1.02-1.37) 
509/509 
2.00 
1.08 (0.95-1.24) 
1.09 (0.95-1.26) 
135/127
< 1.06 
1.00 
1.00 
129/130 
< 2.47 
1.00 
1.00 
120/115 
< 2.41 
1.00 
1.00 
107/127 
< 5.13 
1.00 
1.00 
116/130
> 1.06 to < 1.36 
0.83 (0.58-1.20) 
0.85 (0.58-1.25) 
113/115 
> 2.47 to < 3.19 
1.00 (0.70-1.41) 
1.00 (0.70-1.44) 
103/144 
> 2.41 to < 3.04 
0.71 (0.50-1.02) 
0.71 (0.49-1.04) 
128/124 
> 5.13 to < 6.35 
  1.24 (0.87-1.76) 
1.31 (0.90-1.90) 
123/131 
> 1.36 to < 1.84 
0.88 (0.62-1.26) 
0.88 (0.61-1.29) 
123/133 
>3.19 to < 4.05 
0.94 (0.66-1.34) 
1.00 (0.70-1.45) 
129/131 
> 3.04 to < 3.87 
 1.01 (0.69-1.47) 
0.98 (0.66-1.46) 
123/135 
> 6.35 to < 7.73 
  1.12 (0.79-1.59) 
1.11 (0.77-1.61) 
135/121
> 1.84 
1.05 (0.72-1.53) 
1.13 (0.75-1.68) 
144/131 
> 4.05 
1.12 (0.78-1.62) 
1.16 (0.79-1.71) 
157/119 
> 3.87 
1.41 (0.95-2.09) 
1.42 (0.94-2.16) 
151/123 
> 7.73 
1.55 (1.06-2.27) 
1.66 (1.10-2.51) 
  
  0.72 
0.51 
 
 
0.61 
0.47 
 
 
0.04 
0.04 
 
 
0.05 
0.05 
WOMEN  
Anti-Flic-IgA, no. Ca/Co 
          Matching-adjusted Modelᵃ  
          Fully-adjusted Modelb 
556/556 
0.87 (0.76-1.00) 
0.84 (0.73-0.98) 
176/165 
1.00 
1.00 
159/139 
1.03 (0.76-1.41) 
0.97 (0.70-1.35) 
122/127 
0.86 (0.61-1.21) 
0.81 (0.57-1.16) 
99/125 
0.70 (0.49-1.02) 
0.65 (0.44-0.96) 
 
0.04 
0.02 
Anti-Flic-IgG, no. Ca/Co 
          Matching-adjusted Modelᵃ  
          Fully-adjusted Modelb 
556/556 
0.96 (0.85-1.10) 
0.98 (0.85-1.12) 
131/129 
1.00 
1.00 
139/141 
0.97 (0.69-1.36) 
1.01 (0.71-1.44) 
138/142 
0.96 (0.67-1.36) 
1.06 (0.73-1.53) 
148/144 
1.01 (0.71-1.43) 
1.05 (0.73-1.52) 
 
0.95 
0.74 
Anti-LPS-IgA, no. Ca/Co 
          Matching-adjusted Modelᵃ  
          Fully-adjusted Modelb 
556/556 
0.89 (0.78-1.01) 
0.86 (0.75-0.99) 
165/152 
1.00 
1.00 
161/133 
1.09 (0.78-1.55) 
1.06 (0.74-1.53) 
102/127 
0.72 (0.50-1.03) 
0.67 (0.46-0.98) 
128/144 
0.78 (0.54-1.11) 
0.73 (0.50-1.06) 
 
0.04 
0.02 
Anti-LPS-IgG, no. Ca/Co 
          Matching-adjusted Modelᵃ  
          Fully-adjusted Modelb 
Total-Anti-Flic, no. Ca/Co 
          Matching-adjusted Modelᵃ  
          Fully-adjusted Modelb 
Total-Anti-LPS, no. Ca/Co 
          Matching-adjusted Modelᵃ  
          Fully-adjusted Modelb 
Total-Anti-Flic & LPS, no. Ca/Co 
          Matching-adjusted Modelᵃ  
          Fully-adjusted Modelb 
556/556 
0.95 (0.84-1.08) 
0.94 (0.82-1.08) 
556/556 
0.90 (0.79-1.03) 
0.89 (0.77-1.03) 
556/556 
0.90 (0.79-1.02) 
0.88 (0.76-1.01) 
556/556 
0.88 (0.77-1.01) 
0.86 (0.75-1.00) 
152/141 
1.00 
1.00 
147/137 
1.00 
1..00 
162/152 
1.00 
1.00 
153/140 
1.00 
1.00 
115/135 
0.78 (0.55-1.10) 
0.87 (0.60-1.25) 
136/151 
0.83 (0.59-1.16) 
0.83 (0.59-1.18) 
129/122 
0.98 (0.69-1.38) 
1.01 (0.71-1.46) 
139/141 
0.90 (0.65-1.24) 
0.89 (0.63-1.25) 
158/135 
1.09 (0.78-1.54) 
1.11 (0.78-1.59) 
147/132 
1.02 (0.73-1.42) 
1.09 (0.77-1.54) 
137/134 
0.94 (0.67-1.31) 
0.91 (0.64-1.30) 
144/132 
0.99 (0.71-1.39) 
1.05 (0.74-1.49) 
131/145 
0.83 (0.58-1.19) 
0.83 (0.57-1.21) 
126/136 
0.84 (0.58-1.21) 
0.83 (0.56-1.21) 
128/148 
0.77 (0.53-1.10) 
0.74 (0.51-1.09) 
120/143 
0.73 (0.50-1.05) 
0.70 (0.47-1.02) 
 
0.64 
0.61 
 
0.67 
0.72 
 
0.17 
0.12 
 
0.17 
0.18 
Abbreviation: OD = optical density; SD = standard deviation; OR = odds ratio; CI = confidence interval; Flic = flagellin;  
Ca/Co = case/control; Total-Anti-Flic = anti-flagellin-IgA + anti-flagellin-IgG; Total-Anti-LPS = anti-LPS-IgA + anti-LPS-IgG; 
Total-Anti-Flic & LPS = anti-flagellin-IgA + anti-flagellin-IgG + anti-LPS-IgA + anti-LPS-IgG 
*Quartile cut-off points are same as in Table 2 and were based on the distribution of controls, expressed as optical density 
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ƗPtrend test was based on median values of each quartile 
ᵃMatching-adjusted model based on logistic regression conditioned on matching factors (age, gender, administrative 
centre and date of blood collection)  
ᵇBased on matching factors plus adjustments for established confounding factors (smoking, alcohol consumption, body 
mass index, weight circumference, physical activity, education, and total daily dietary energy consumption, fibre intake, 
fruits and vegetable intakes, meat and processed meat consumption)  
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Table 3:  ORs (95% CI) for risk of colon cancer by quartile of baseline biomarkers of anti-LPS- and anti-flagellin-
IgA and IgG: Stratified by sex   
Serum Immunoglobulins 
Against LPS and Flagellin, OD 
Continuous Quartiles* 
Ptrend (per 1-SD Increase) 
OR(95% CI) 
Q1 
OR 
Q2 
OR (95% CI) 
Q3 
OR (95% CI) 
Q4 
OR (95% CI) 
MEN   
Anti-Flic-IgA, no. Ca/Co 
        SD/Cut-point 
        Matching-adjusted Modelᵃ  
        Fully-adjusted Modelb 
298/298 
0.74 
1.01 (0.85-1.20) 
0.99 (0.83-1.19) 
55/61 
< 0.85 
1.00 
1.00 
79/72 
> 0.85 to < 1.23 
1.20 (0.75-1.93) 
1.29 (0.78-2.13) 
79/84 
> 1.23 to < 1.72 
1.03 (0.64-1.67) 
1.13 (0.67-1.88) 
85/81 
> 1.72 
1.14 (0.71-1.83) 
1.09 (0.66-1.80) 
 
 
0.73 
0.91 
Anti-Flic-IgG, no. Ca/Co 
        SD/Cut-point 
        Matching-adjusted Modelᵃ  
        Fully-adjusted Modelb 
298/298 
0.79 
1.00 (0.84-1.20) 
1.04 (0.86-1.27) 
77/83
< 1.47 
1.00 
1.00 
76/67
> 1.47 to < 2.00 
1.25 (0.77-2.02) 
1.37 (0.82-2.29) 
76/79 
> 2.00 to < 2.58 
1.06 (0.65-1.74) 
1.23 (0.72-2.09) 
69/69
> 2.58 
1.10 (0.66-1.82) 
1.25 (0.72-2.17) 
 
0.90 
0.54 
Anti-LPS-IgA, no. Ca/Co 
        SD/Cut-point 
        Matching-adjusted Modelᵃ  
        Fully-adjusted Modelb 
298/298 
0.72 
1.19 (0.99-1.43) 
1.18 (0.97-1.44) 
69/69 
< 1.23 
1.00 
1.00 
67/83 
> 1.23 to < 1.70 
0.81 (0.51-1.31) 
0.85 (0.51-1.41) 
71/77 
> 1.70 to < 2.20 
0.95 (0.58-1.55) 
0.93 (0.54-1.60) 
91/69 
> 2.20 
1.46 (0.87-2.45) 
1.44 (0.83-2.51) 
 
 
0.12 
0.18 
Anti-LPS-IgG, no. Ca/Co 
        SD/Cut-point 
        Matching-adjusted Modelᵃ  
        Fully-adjusted Modelb 
Total-Anti-Flic, no. Ca/Co 
        SD/Cut-point 
        Matching-adjusted Modelᵃ  
        Fully-adjusted Modelb 
Total-Anti-LPS, no. Ca/Co 
        SD/Cut-point 
        Matching-adjusted Modelᵃ  
        Fully-adjusted Modelb 
Total-Anti-Flic & LPS, no. Ca/Co 
        SD/Cut-point 
        Matching-adjusted Modelᵃ  
        Fully-adjusted Modelb 
298/298 
0.60 
1.14 (0.97-1.35) 
1.20 (1.00-1.44) 
298/298 
1.26 
1.01 (0.85-1.20) 
1.02 (0.84-1.22) 
298/298 
1.10 
1.22 (1.02-1.46) 
1.25 (1.03-1.53) 
298/298 
2.00 
1.11 (0.94-1.33) 
1.14 (0.94-1.37) 
82/76 
< 1.08 
1.00 
1.00 
69/76 
< 2.50 
1.00 
1.00 
63/73 
< 2.47 
1.00 
1.00 
61/76 
< 5.28 
1.00 
1.00 
61/81 
> 1.08 to < 1.41 
0.69 (0.43-1.11) 
0.77 (0.46-1.28) 
75/70 
> 2.50 to < 3.26 
1.21 (0.75-1.95) 
1.21 (0.73-2.01) 
68/83 
> 2.47 to < 3.10 
0.97 (0.62-1.51) 
1.11 (0.69-1.78) 
78/80 
> 5.28 to < 6.46 
1.22 (0.78-1.91) 
1.42 (0.88-2.31) 
74/77 
> 1.41 to < 1.86 
0.88 (0.55-1.40) 
0.90 (0.54-1.49) 
71/79 
> 3.26 to < 4.11 
1.01 (0.63-1.62) 
1.11 (0.67-1.85) 
72/74 
> 3.10 to < 3.93 
1.18 (0.74-1.90) 
1.26 (0.75-2.10) 
71/70 
> 6.46 to < 7.91 
1.33 (0.83-2.13) 
1.42 (0.86-2.37) 
81/64 
> 1.86 
1.19 (0.73-1.94) 
1.34 (0.79-2.28) 
83/73 
> 4.11 
1.31 (0.80-2.15) 
1.30 (0.76-2.23) 
95/68 
> 3.93 
1.83 (1.11-3.02) 
1.97 (1.15-3.39) 
88/72 
> 7.91 
1.65 (1.00-2.72) 
1.80 (1.04-3.10) 
 
 
0.33 
0.21 
 
 
0.45 
0.43 
 
 
0.01 
0.01 
 
 
0.05 
0.049 
WOMEN**       
Anti-Flic-IgA, no. Ca/Co 
        Matching-adjusted Modelᵃ  
        Fully-adjusted Modelb 
369/369 
0.83 (0.70-0.97) 
0.80 (0.36-0.96) 
119/107 
1.00 
1.00 
103/94 
0.96 (0.66-1.40) 
0.94 (0.63-1.39) 
86/83 
0.89 (0.59-1.32) 
0.84 (0.55-1.29) 
61/85 
0.63 (0.40-0.97) 
0.59 (0.37-0.93) 
 
0.05 
0.03 
Anti-Flic-IgG, no. Ca/Co 
        Matching-adjusted Modelᵃ  
        Fully-adjusted Modelb 
369/369 
0.94 (0.80-1.10) 
0.95 (0.80-1.13) 
89/84 
1.00 
1.00 
94/100 
0.89 (0.60-1.33) 
0.94 (0.62-1.44) 
87/88 
0.93 (0.61-1.44) 
1.07 (0.68-1.69) 
99/97 
0.96 (0.62-1.48) 
1.01 (0.64-1.60) 
 
0.94 
0.84 
Anti-LPS-IgA, no. Ca/Co 
        Matching-adjusted Modelᵃ  
        Fully-adjusted Modelb 
369/369 
0.90 (0.77-1.05) 
0.89 (0.75-1.04) 
104/98 
1.00 
1.0 
112/84 
1.27 (0.83-1.94) 
1.26 (0.80-1.99) 
65/90 
0.68 (0.43-1.05) 
0.66 (0.42-1.06) 
88/97 
0.84 (0.55-1.29) 
0.81 (0.51-1.28) 
 
0.10 
0.08 
Anti-LPS-IgG, no. Ca/Co 
        Matching-adjusted Modelᵃ  
        Fully-adjusted Modelb 
Total-Anti-Flic, no. Ca/Co 
        Matching-adjusted Modelᵃ  
        Fully-adjusted Modelb 
Total-Anti-LPS, no. Ca/Co 
        Matching-adjusted Modelᵃ  
        Fully-adjusted Modelb 
Total-Anti-Flic & LPS, no. Ca/Co 
        Matching-adjusted Modelᵃ  
        Fully-adjusted Modelb 
369/369 
0.85 (0.72-0.99) 
0.84 (0.71-0.99) 
369/369 
0.85 (0.72-1.01) 
0.85 (0.71-1.01) 
369/369 
0.85 (0.73-0.99) 
0.84 (0.71-0.99) 
369/369 
0.83 (0.71-0.98) 
0.82 (0.69-0.97) 
117/91
1.00 
1.00 
96/91 
1.00 
1.00 
116/94 
1.00 
1.00 
109/91 
1.00 
1.00 
78/86
0.68 (0.44-1.05) 
0.74 (0.47-1.16) 
104/97 
1.00 (0.67-1.50) 
1.08 (0.71-1.66) 
81/85 
0.76 (0.50-1.14) 
0.74 (0.48-1.15) 
93/87 
0.88 (0.59-1.33) 
0.90 (0.58-1.39) 
91/90 
0.76 (0.51-1.15) 
0.74 (0.48-1.14) 
91/88 
0.97 (0.64-1.47) 
1.10 (0.71-1.72) 
89/92 
0.77 (0.52-1.15) 
0.75 (0.49-1.15) 
87/97 
0.73 (0.48-1.11) 
0.80 (0.52-1.24) 
83/102
0.58 (0.37-0.90) 
0.57 (0.35-0.91) 
78/93 
0.76 (0.49-1.19) 
0.75 (0.46-1.21) 
83/98 
0.64 (0.42-0.99) 
0.62 (0.39-0.98) 
80/94 
0.68 (0.44-1.05) 
0.66 (0.42-1.05) 
0.03 
0.02 
 
0.26 
0.31 
 
0.06 
0.049 
 
0.05 
0.07 
Abbreviation: OD = optical density; Flic = Flagellin; Ca/Co = Case/Control; Total-Anti-Flic = anti-flagellin-IgA + anti-flagellin-IgG; Total-Anti-
LPS = anti-LPS-IgA + anti-LPS-IgG; Total-Anti-Flic & LPS = anti-flagellin Ig-A + anti-flagellin IgG + anti-LPS IgA + anti-LPS-IgG 
*Quartile cut-off points were based on the distribution of controls, expressed as optical density readings  **Quartile cut-off points are 
same as those in MEN ƗPtrend test was based on median values of each quartile ᵃMatching-adjusted model based on logistic regression 
conditioned on matching factors (age, gender, administrative centre and date of blood collection) ᵇBased on matching factors plus 
adjustments for established confounding factors (smoking, alcohol consumption, body mass index, weight circumference, physical activity, 
education, and total daily dietary energy consumption, fibre intake, fruits and vegetable intakes, meat and processed meat consumption)  
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Table 4:  ORs (95% CI) for risk of rectal cancer by quartile of baseline biomarkers of anti-LPS- and anti-flagellin-
IgA and IgG: Stratified by sex   
Serum Immunoglobulins 
Against LPS and Flagellin, OD 
Continuous   Quartiles* 
Ptrend (per 1-SD Increase) 
OR(95% CI) 
Q1 
 
Q2 
OR (95% CI) 
Q3 
OR (95% CI) 
Q4 
OR (95% CI) 
MEN   
Anti-Flic-IgA, no. Ca/Co 
      SD/Cut-point 
      Matching-adjusted Modelᵃ  
      Fully-adjusted Modelb 
211/211 
0.69 
1.07 (0.88-1.31) 
1.08 (0.87-1.33) 
38/42 
< 0.75 
1.00 
1.00 
39/49 
> 0.75 to < 1.06 
0.87 (0.48-1.60) 
0.98 (0.50-1.92) 
72/60 
> 1.06 to < 1.59 
1.32 (0.76-2.28) 
1.34 (0.75-2.41) 
62/60 
> 1.59 
1.17 (0.64-2.14) 
1.30 (0.68-2.49) 
 
 
0.34 
0.28 
Anti-Flic-IgG, no. Ca/Co 
      SD/Cut-point 
      Matching-adjusted Modelᵃ  
      Fully-adjusted Modelb 
211/211 
0.76 
0.90 (0.73-1.11) 
0.95 (0.76-1.19) 
65/54
< 1.45 
1.00 
1.00 
48/58
> 1.45 to < 1.95 
0.70 (0.42-1.17) 
0.69 (0.39-1.23) 
52/46
> 1.95 to < 2.60 
0.95 (0.54-1.67) 
0.94 (0.51-1.71) 
46/53 
> 2.60 
0.72 (0.40-1.29) 
0.78 (0.41-1.48) 
 
0.37 
0.57 
Anti-LPS-IgA, no. Ca/Co 
      SD/Cut-point 
      Matching-adjusted Modelᵃ  
      Fully-adjusted Modelb 
211/211 
0.71 
1.17 (0.94-1.46) 
1.19 (0.93-1.53) 
40/44 
< 1.14 
1.00 
1.00 
62/52 
> 1.14 to < 1.57 
1.30 (0.71-2.37) 
1.43 (0.75-2.73) 
45/61 
> 1.57 to < 2.02 
0.80 (0.41-1.58) 
0.79 (0.38-1.66) 
64/54 
> 2.02 
1.33 (0.68-2.62) 
1.40 (0.67-2.94) 
 
 
0.67 
0.68 
Anti-LPS-IgG, no. Ca/Co 
      SD/Cut-point 
      Matching-adjusted Modelᵃ  
      Fully-adjusted Modelb 
Total-Anti-Flic, no. Ca/Co 
      SD/Cut-point 
      Matching-adjusted Modelᵃ  
      Fully-adjusted Modelb 
Total-Anti-LPS, no. Ca/Co 
      SD/Cut-point 
      Matching-adjusted Modelᵃ  
      Fully-adjusted Modelb 
Total-Anti-Flic & LPS, no. Ca/Co 
      SD/Cut-point 
      Matching-adjusted Modelᵃ  
      Fully-adjusted Modelb 
211/211 
0.61 
1.01 (0.84-1.23) 
1.04 (0.85-1.28) 
211/211 
1.17 
0.98 (0.80-1.19) 
1.01 (0.82-1.25) 
211/211 
1.12 
1.11 (0.89-1.37) 
1.13 (0.90-1.43) 
211/211 
1.98 
1.04 (0.85-1.28) 
1.08 (0.86-1.35) 
53/53 
< 1.01 
1.00 
1.00 
59/56 
< 2.40 
1.00 
1.00 
53/42 
< 2.28 
1.00 
1.00 
43/52 
< 4.95 
1.00 
1.00 
61/49 
> 1.01 to < 1.33 
1.26 (0.73-2.15) 
1.20 (0.67-2.14) 
44/44 
> 2.40 to < 3.10 
0.95 (0.55-1.64) 
0.95 (0.53-1.68) 
36/61 
> 2.28 to < 2.91 
0.44 (0.23-0.82) 
0.37 (0.19-0.72) 
50/46 
> 4.95 to <  6.11 
1.34 (0.75-2.41) 
1.27 (0.68-2.39) 
44/54 
> 1.33 to < 1.78 
0.81 (0.47-1.40) 
0.78 (0.43-1.39) 
52/54 
> 3.10 to < 3.99 
0.91 (0.54-1.55) 
0.92 (0.52-1.61) 
59/58 
> 2.91 to < 3.75 
0.84 (0.46-1.54) 
0.77 (0.40-1.50) 
62/59 
> 6.11 to < 7.55 
1.29 (0.75-2.21) 
1.24 (0.69-2.21) 
53/55 
> 1.78  
0.92 (0.52-1.63) 
0.98 (0.53-1.80) 
56/57 
> 3.99 
0.93 (0.54-1.59) 
1.01 (0.56-1.81) 
63/50 
> 3.75 
1.06 (0.56-2.01) 
1.16 (0.58-2.32) 
56/54 
>7.55 
1.30 (0.71-2.39) 
1.49 (0.77-2.90) 
 
 
0.51 
0.63 
 
 
0.75 
0.99 
 
 
0.42 
0.36 
 
 
0.44 
0.29 
WOMEN**       
Anti-Flic-IgA, no. Ca/Co 
      Matching-adjusted Modelᵃ  
      Fully-adjusted Modelb 
187/187 
0.99 (0.77-1.28) 
0.96 (0.73-1.26) 
61/58 
1.00 
1.00 
43/50 
0.84 (0.49-1.43) 
0.72 (0.41-1.26) 
41/40 
0.98 (0.52-1.87) 
0.82 (0.41-1.64) 
42/39 
1.04 (0.54-2.00) 
0.95 (0.47-1.92) 
 
0.83 
0.92 
Anti-Flic-IgG, no. Ca/Co 
      Matching-adjusted Modelᵃ  
      Fully-adjusted Modelb 
187/187 
1.01 (0.82-1.26) 
  1.01 (0.80-1.28) 
43/46 
1.00 
1.00 
46/41 
1.18 (0.65-2.16) 
1.17 (0.62-2.20) 
49/54 
0.98 (0.54-1.79) 
1.06 (0.55-2.02) 
49/46 
1.13 (0.62-2.07) 
1.15 (0.60-2.21) 
 
0.84 
0.77 
Anti-LPS-IgA, no. Ca/Co 
      Matching-adjusted Modelᵃ  
      Fully-adjusted Modelb 
187/187 
0.86 (0.68-1.10) 
0.82 (0.63-1.07) 
53/56 
1.00 
1.00 
58/47 
1.32 (0.73-2.40) 
1.34 (0.71-2.52) 
37/40 
0.98 (0.53-1.81) 
0.89 (0.47-1.71) 
39/44 
0.92 (0.46-1.83) 
0.84 (0.40-1.74) 
 
0.58 
0.39 
Anti-LPS-IgG, no. Ca/Co 
      Matching-adjusted Modelᵃ  
      Fully-adjusted Modelb  
Total-Anti-Flic, no. Ca/Co 
      Matching-adjusted Modelᵃ  
      Fully-adjusted Modelb  
Total-Anti-LPS, no. Ca/Co 
      Matching-adjusted Modelᵃ  
      Fully-adjusted Modelb  
Total-Anti-Flic & LPS, no. Ca/Co 
      Matching-adjusted Modelᵃ  
      Fully-adjusted Modelb 
187/187 
1.21 (0.96-1.53) 
1.22 (0.96-1.56) 
187/187 
1.01 (0.80-1.27) 
  0.99 (0.77-1.27) 
        187/187 
1.03 (0.81-1.32) 
1.00 (0.77-1.31)     
187/187 
1.02 (0.80-1.31) 
1.00 (0.76-1.30) 
39/47
1.00 
1.00 
49/44 
1.00 
1.00 
49/58 
1.00 
1.00 
49/48 
1.00 
1.00 
39/50
0.94 (0.52-1.72) 
1.11 (0.59-2.10) 
38/55 
0.64 (0.36-1.14) 
0.61 (0.33-1.11) 
43/38 
1.38 (0.75-2.54) 
1.49 (0.78-2.85) 
45/53 
0.84 (0.48-1.48) 
0.80 (0.44-1.46) 
61/46
1.94 (1.01-3.73) 
2.21 (1.11-4.40) 
57/46 
1.10 (0.62-1.96) 
1.10 (0.59-2.03) 
49/41 
1.48 (0.80-2.75) 
1.44 (0.77-2.72) 
50/42 
1.16 (0.64-2.08) 
1.17 (0.63-2.19) 
48/44 
1.60 (0.83-3.09) 
1.74 (0.87-3.50) 
43/42 
0.93 (0.50-1.75) 
0.92 (0.47-1.80) 
46/50 
1.15 (0.61-2.17) 
1.13 (0.58-2.23) 
43/44 
0.95 (0.50-1.79) 
0.91 (0.46-1.78) 
0.10 
0.07 
 
0.69 
0.73 
 
0.64 
0.73 
 
0.80 
0.85 
Abbreviation: OD = optical density; Flic = Flagellin; Ca/Co = Case/Control; Total-Anti-Flic = anti-flagellin-IgA + anti-flagellin-IgG; Total-Anti-
LPS = anti-LPS-IgA + anti-LPS-IgG; Total-Anti-Flic & LPS = anti-flagellin Ig-A + anti-flagellin IgG + anti-LPS IgA + anti-LPS-IgG 
*Quartile cut-off points were based on the distribution of controls, expressed as optical density readings **Quartile cut-off points are 
same as those in MEN ƗPtrend test was based on median values of each quartile ᵃMatching-adjusted model based on logistic regression 
conditioned on matching factors (age, gender, administrative centre and date of blood collection)  ᵇBased on matching factors plus 
adjustments for established confounding factors (smoking, alcohol consumption, body mass index, weight circumference, physical activity, 
education, and total daily dietary energy consumption, fibre intake, fruits and vegetable intakes, meat and processed meat consumption)  
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